- Title: Subtitle
- 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Trial
- Creators
- Jonathan Strosberg - Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USAEdward Wolin - University of KentuckyBeth Chasen - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USAMatthew Kulke - DanaDavid Bushnell - University of IowaMartyn Caplin - The Royal Free HospitalRichard P. Baum - Zentralklin, Bad Berka, GermanyErik Mittra - Stanford UniversityTimothy Hobday - Mayo ClinicAndrew Hendifar - Cedars-Sinai Medical CenterKjell Öberg - Uppsala UniversityMaribel Lopera Sierra - Adv Accelerator Applicat, New York, NY USADik Kwekkeboom - Erasmus MCPhilippe Ruszniewski - Hop Beaujon, Clichy, FranceEric Krenning - Erasmus MC
- Resource Type
- Abstract
- Publication Details
- Pancreas, Vol.45(3), p.483
- ISSN
- 0885-3177
- eISSN
- 1536-4828
- Comment
- DOI: 10.1097/MPA.0000000000000615
- Language
- English
- Date published
- 2016
- Academic Unit
- Radiology
- Record Identifier
- 9984320014902771
Abstract
177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Trial
Pancreas, Vol.45(3), p.483
2016
Abstract
Details
Metrics
8 Record Views